Dexcom Reports Third Quarter 2026 Financial Results
Business Wire•29/10/2026•16:03 ET
1
Key Highlights
- ➤Revenue $1.344 billion, up 11% year-over-year
- ➤GAAP operating income $327.2 million, margin expanded 420 basis points
- ➤2026 revenue guidance raised to $5.20-$5.25 billion
- ➤Share repurchase authorization approved for up to $1.0 billion
- ➤Dexcom launched redesigned Stelo experience and advanced G7 15 Day rollout
Expert Statements
Jake Leach, President and CEO of Dexcom
“This quarter, we continued to build momentum across the business, delivering strong revenue growth and margin progression, strengthening our clinical evidence, and advancing key product and operational initiatives,”
Jake Leach, President and CEO of Dexcom
“This performance enabled us to again raise our full-year revenue and operating margin guidance and reinforces our confidence in our ability to deliver on the long-term objectives we outlined at Investor Day.”
DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended September 30, 2026.
* Revenue grew 11% year-over-year to $1.344 billion on a reported basis and 11% year-over-year on an organic(1) basis.
Get started
Create a free account to read the full story.